Oligometastases revisited

Nature Reviews Clinical Oncology

Volumn 8, Issue 6, 2011, Pages 378-382

  Weichselbaum, Ralph R ^a   Hellman, Samuel ^a  

^a UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; MOLECULAR MARKER; OXALIPLATIN;

CANCER ADJUVANT THERAPY; CANCER CONTROL; CANCER MODEL; CANCER SURVIVAL; DISEASE COURSE; HUMAN; LIVER METASTASIS; LIVER RESECTION; LUNG METASTASIS; LUNG RESECTION; METASTASIS; NONHUMAN; OLIGOMETASTASIS; ONCOLOGICAL PARAMETERS; PREVALENCE; PRIMARY TUMOR; PRIORITY JOURNAL; REVIEW; SURVIVAL RATE; SURVIVAL TIME; TREATMENT RESPONSE; TUMOR DORMANCY; TUMOR GENE; VISCERAL METASTASIS;

HUMANS; NEOPLASM METASTASIS; NEOPLASMS;

EID: 79958030956     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2011.44     Document Type: Review

References (40)

1. th edn (Springer, New York, 2010).
2. Hellman, S. & Weichselbaum, R. R. Oligometastases. J. Clin. Oncol. 13, 8-10 (1995).
3. Hughes, K. S. et al. Resection of the liver for colorectal carcinoma metastases: a multi-institutional study of patterns of recurrence. Surgery 100, 278-284 (1986). (Pubitemid 16070861)
4. Nordlinger, B. et al. Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection, based on 1568 patients. Association Française de Chirurgie. Cancer 77, 1254-1262 (1996). (Pubitemid 26102322)
5. Fong, Y., Fortner, J., Sun, R. L., Brennan, M. F. & Blumgart, L. H. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann. Surg. 230, 309-318 (1999).
6. Pawlik, T. M. et al. Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases. Ann. Surg. 241, 715-722 (2005).
7. Pastorino, U. et al. Long-term results of lung metastasectomy: prognostic analyses based on 5206 cases. The International Registry of Lung Metastases. J. Thorac. Cardiovasc. Surg. 113, 37-49 (1997). (Pubitemid 27034340)
8. Strong, V. E. et al. Laparoscopic adrenalectomy for isolated adrenal metastasis. Ann. Surg. Oncol. 14, 3392-3400 (2007). (Pubitemid 350160106)
9. Ben-Josef, E. & Lawrence, T. S. Using a bigger hammer: the role of stereotactic body radiotherapy in the management of oligometastases. J. Clin. Oncol. 27, 1537-1539 (2009).
10. Salama, J. K. et al. An initial report of a radiation dose-escalation trial in patients with one to five sites of metastatic disease. Clin. Cancer Res. 14, 5255-5259 (2008).
11. Rusthoven, K. E. et al. Multi-institutional phase I/II trial of stereotactic body radiation therapy for lung metastases. J. Clin. Oncol. 27, 1579-1584 (2009).
12. Lee, M. T. et al. Phase I study of individualized stereotactic body radiotherapy of liver metastases. J. Clin. Oncol. 27, 1585-1591 (2009).
13. Macdermed, D. M., Weichselbaum, R. R. & Salama, J. K. A rationale for the targeted treatment of oligometastases with radiotherapy. J. Surg. Oncol. 98, 202-206 (2008).
14. Fakiris, A. J. et al. Stereotactic body radiation therapy for early-stage non-small-cell lung carcinoma: four-year results of a prospectice phase II study. Int. J. Radiat. Oncol. Biol. Phys. 75, 677-682 (2009).
15. Minn, A. J. et al. Genes that mediate breast cancer metastasis to lung. Nature 436, 518-524 (2005). (Pubitemid 41112921)
16. Minn, A. J. et al. Lung metastasis genes couple breast tumor size and metastatic spread. Proc. Natl Acad. Sci. USA 104, 6740-6745 (2007). (Pubitemid 47175571)
17. Kaplan, R. N., Psaila, B. & Lyden, D. Bone marrow cells in the 'pre-metastatic niche': within bone and beyond. Cancer Metastasis Rev. 25, 521-529 (2006). (Pubitemid 46071861)
18. Erler, J. T. et al. Lysyl oxidase is essential for hypoxia-induced metastasis. Nature 440, 1222-1226 (2006).
19. Giacchetti, S. et al. Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery. Ann. Oncol. 10, 663-669 (1999). (Pubitemid 29342371)
20. Lévi, F. et al. Cetuximab and circadian chronomodulated chemotherapy as salvage treatment for metastatic colorectal cancer (mCRC): safety, efficacy and improved secondary surgical resectability. Cancer Chemother. Pharmacol. 67, 339-348 (2011).
21. Paget, S. The distribution of secondary growths in cancer of the breast. 1889. Cancer Metastasis Rev. 8, 98-101 (1989).
22. Deng, C. X. BRCA1: cell cycle checkpoint, genetic instability, DNA damage response and cancer evolution. Nucleic Acids Res. 34, 1416-1426 (2006).
23. Rajagopalan, H. & Lengauer, C. Aneuploidy and cancer. Nature 432, 338-341 (2004). (Pubitemid 39551662)
24. Gupta, G. P. & Massagué, J. Cancer metastasis: building a framework. Cell 127, 679-695 (2006). (Pubitemid 44781029)
25. Aguirre-Ghiso, J. A. Models, mechanisms and clinical evidence for cancer dormancy. Nat. Rev. Cancer 7, 834-846 (2007). (Pubitemid 350006258)
26. Fokas, E., Engenhart-Cabillic, R., Daniilidis, K., Rose, F. & An, H. X. Metastasis: the seed and soil theory gains identity. Cancer Metastasis Rev. 26, 705-715 (2007). (Pubitemid 350115118)
27. Uhr, J. W., Scheuermann, R. H, Street, N. E. & Vitetta, E. S. Cancer dormancy: opportunities for new therapeutic approaches. Nat. Med. 3, 505-509 (1997). (Pubitemid 27198646)
28. Goss, P. E. & Chambers, A. F. Does tumour dormancy offer a therapeutic target? Nat. Rev. Cancer 10, 871-877 (2010).
29. Dunn, G. P., Koebel, C. M. & Schreiber, R. D. Interferons, immunity and cancer immunoediting. Nat. Rev. Immunol. 6, 836-848 (2006). (Pubitemid 44631652)
30. Fidler, I. J. & Kripke, M. L. Metastasis results from preexisting variant cells within a malignant tumor. Science 197, 893-895 (1977). (Pubitemid 8168759)
31. Chambers, A. F, Hill, R. P. & Ling, V. Tumor heterogeneity and stability of the metastatic phenotype of mouse KHT sarcoma cells. Cancer Res. 41, 1368-1372 (1981). (Pubitemid 11146766)
32. Harris, J. F., Chambers, A. F., Hill, R. P. & Ling, V. Metastatic variants are generated spontaneously at a high rate in mouse KHT tumor. Proc. Natl Acad. Sci. USA 79, 5547-5551 (1982). (Pubitemid 13197681)
33. Cillo, C., Dick, J. E., Ling, V. & Hill, R. P. Generation of drug-resistant variants in metastatic B16 mouse melanoma cell lines. Cancer Res. 47, 2604-2608 (1987). (Pubitemid 17083148)
34. Khodarev, N. N. et al. STAT1 pathway mediates amplification of metastatic potential and resistance to therapy. PLoS ONE 4, e5821 (2009).
35. Khodarev, N. N. et al. STAT1 is overexpressed in tumors selected for radioresistance and confers protection from radiation in transduced sensitive cells. Proc. Natl Acad. Sci. USA 101, 1714-1719 (2004). (Pubitemid 38234220)
36. Weichselbaum, R. R. et al. An interferon-related gene signature for DNA damage resistance is a predictive marker for chemotherapy and radiation for breast cancer. Proc. Natl Acad. Sci. USA 105, 18490-18495 (2008).
37. Wuttig, D. et al. Gene signatures of pulmonary metastases of renal cell carcinoma reflect the disease-free interval and the number of metastases per patient. Int. J. Cancer 125, 474-482 (2009).
38. Jones, J. et al. Gene signatures of progression and metastasis in renal cell cancer. Clin. Cancer Res. 11, 5730-5739 (2005). (Pubitemid 41170297)
39. Campbell, P. J. et al. The patterns and dynamics of genomic instability in metastatic pancreatic cancer. Nature 467, 1109-1113 (2010).
40. Yachida, S. et al. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 467, 1114-1117 (2010).